Zolsketil pegylated liposomal Den europeiske union - norsk - EMA (European Medicines Agency)

zolsketil pegylated liposomal

accord healthcare s.l.u. - doxorubicin hydrochloride, liposomal - ovarian neoplasms; sarcoma, kaposi; multiple myeloma - doxorubicin - zolsketil pegylated liposomal is a medicine used to treat the following types of cancer in adults:• breast cancer that has spread to other parts of the body in patients at risk of heart problems. zolsketil pegylated liposomal is used on its own for this disease;• advanced ovarian cancer in women whose previous treatment including a platinum-based cancer medicine has stopped working;• multiple myeloma (a cancer of the white blood cells in the bone marrow), in patients with progressive disease who have received at least one other treatment in the past and have already had, or are unsuitable for, a bone marrow transplantation. zolsketil pegylated liposomal is used in combination with bortezomib (another cancer medicine);• kaposi’s sarcoma in patients with aids who have a very damaged immune system. kaposi’s sarcoma is a cancer that causes abnormal tissue to grow under the skin, on moist body surfaces or on internal organs. zolsketil pegylated liposomal contains the active substance doxorubicin and is a ‘hybrid medicine’. this means that it is similar to a ‘reference medicine’ containing the same active substance called adriamycin. however, in zolsketil pegylated liposomal the active substance is enclosed in tiny fatty spheres called liposomes, whereas this is not the case for adriamycin.

Doxorubicin Ebewe 2 mg/ ml Norge - norsk - Statens legemiddelverk

doxorubicin ebewe 2 mg/ ml

ebewe pharma ges.m.b.h nfg. kg - doksorubicinhydroklorid - injeksjonsvæske, oppløsning - 2 mg/ ml

Doxorubicin Accord 2 mg/ ml Norge - norsk - Statens legemiddelverk

doxorubicin accord 2 mg/ ml

accord healthcare b.v. - doksorubicinhydroklorid - konsentrat til infusjonsvæske, oppløsning - 2 mg/ ml

Celdoxome pegylated liposomal Den europeiske union - norsk - EMA (European Medicines Agency)

celdoxome pegylated liposomal

yes pharmaceutical development services gmbh - doxorubicin hydroklorid - breast neoplasms; ovarian neoplasms; multiple myeloma; sarcoma, kaposi - antineoplastiske midler - celdoxome pegylated liposomal is indicated in adults:as monotherapy for patients with metastatic breast cancer, where there is an increased cardiac risk. or treatment of advanced ovarian cancer in women who have failed a first-line platinum-based chemotherapy regimen. in combination with bortezomib for the treatment of progressive multiple myeloma in patients who have received at least one prior therapy and who have already undergone or are unsuitable for bone marrow transplant. for treatment of aids-related kaposi’s sarcoma (ks) in patients with low cd4 counts (< 200 cd4 lymphocytes/mm3) and extensive mucocutaneous or visceral disease. celdoxome pegylated liposomal may be used as first-line systemic chemotherapy, or as second line chemotherapy in aids-ks patients with disease that has progressed with, or in patients intolerant to, prior combination systemic chemotherapy comprising at least two of the following agents: a vinca alkaloid, bleomycin and standard doxorubicin (or other anthracycline).

Caelyx pegylated liposomal Den europeiske union - norsk - EMA (European Medicines Agency)

caelyx pegylated liposomal

baxter holding b.v. - doxorubicin hydroklorid - sarcoma, kaposi; multiple myeloma; ovarian neoplasms; breast neoplasms - antineoplastiske midler - caelyx pegylated liposomal er angitt:som monoterapi til pasienter med metastatisk brystkreft, hvor det er en økt kardial risiko;for behandling av avansert eggstokkreft hos kvinner som har mislyktes i et første-linje platinum-basert kjemoterapi diett, i kombinasjon med bortezomib for behandling av progressive myelomatose hos pasienter som har fått minst ett før behandling, og som har gjennomgått eller er uegnet for bein marg transplantasjon, for behandling av aids-relatert kaposis sarkom (ks) hos pasienter med lave cd4 teller (.

Myocet liposomal (previously Myocet) Den europeiske union - norsk - EMA (European Medicines Agency)

myocet liposomal (previously myocet)

teva b.v. - doxorubicin hydroklorid - bryst neoplasms - antineoplastiske midler - myocet liposomal, i kombinasjon med cyklofosfamid, er indikert for det første-linje behandling av metastatisk brystkreft i voksen kvinne.

Adriamycin 10 mg Norge - norsk - Statens legemiddelverk

adriamycin 10 mg

pfizer as - doksorubicinhydroklorid - pulver til injeksjonsvæske, oppløsning - 10 mg

Adriamycin 2 mg/ ml Norge - norsk - Statens legemiddelverk

adriamycin 2 mg/ ml

pfizer as - doksorubicinhydroklorid - injeksjonsvæske, oppløsning - 2 mg/ ml

Adriamycin 50 mg Norge - norsk - Statens legemiddelverk

adriamycin 50 mg

pfizer as - doksorubicinhydroklorid - pulver til injeksjonsvæske, oppløsning - 50 mg

Gemcitabin Fresenius Kabi 200 mg Norge - norsk - Statens legemiddelverk

gemcitabin fresenius kabi 200 mg

fresenius kabi norge as - halden - gemcitabinhydroklorid - pulver til infusjonsvæske, oppløsning - 200 mg